Ruxolitinib
RA Mesa, U Yasothan, P Kirkpatrick - Nature reviews Drug discovery, 2012 - nature.com
RA Mesa, U Yasothan, P Kirkpatrick
Nature reviews Drug discovery, 2012•nature.comAbstract In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of
Janus kinases, was approved by the US Food and Drug Administration for the treatment of
patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-
polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.
Janus kinases, was approved by the US Food and Drug Administration for the treatment of
patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-
polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.
Abstract
In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.
nature.com